Researchers introduced a ferritin aggregation cell engager (FACE) that enhances CAR‑T efficacy against refractory leukemias by bridging CAR‑T cells and tumor cells via CD71, improving avidity without genetic modification of the CAR construct. Preclinical data showed FACE‑augmented CAR‑T matched conventional efficacy with one‑fifth of the cell dose and lowered cytokine release risk in patient‑derived xenograft models. The work, published in Cell, leverages CD71 expression on both CAR‑T preparations and leukemia cells to create a reversible, protein‑based synapse that strengthens cell–cell engagement. FACE can be added to manufacturing workflows as a culture supplement, enabling integration without additional genetic engineering steps or regulatory complexity associated with new CAR designs. If translated clinically, FACE could reduce manufacturing burdens and cell‑dose requirements, offering a pragmatic route to improve CAR‑T performance in relapsed/refractory settings.